United States Next-Generation Cancer Therapeutics Market Size, Share, Growth, and Industry Analysis, By Therapy Type (Targeted Therapy (Small Molecule Inhibitors), Immunotherapy Checkpoint Inhibitors (PD-1, PD-L1, CTLA-4) CAR-T Cell Therapy Cancer Vaccines, Gene Therapy, Cell Therapy (e.g., TILs, NK cells) ), By Cancer Type (Lung Cancer, Breast Cancer, Colorectal Cancer, Blood Cancers (Leukemia, Lymphoma, Myeloma) ) and Forecast, 2026-2034

United States Next-Generation Cancer Therapeutics Market Trends

Precision Oncology, ADCs and Engineered Cell Platforms Reshape Treatment

Technology migration is accelerating from broad cytotoxic regimens toward biomarker-directed drugs, ADCs and engineered immune-cell platforms. FDA's 2024 approval of lifileucel represented the first tumor-derived T-cell therapy approval; its pivotal evidence included 73 patients at the recommended dose and a 31.5% objective response rate, including 4.1% complete and 27.4% partial responses.

ADC innovation is simultaneously expanding treatment options. Datroway's pivotal breast-cancer trial included 732 patients across 166 sites and 20 countries, with a 6 mg/kg IV dose every 3 weeks. In 2026, its TNBC indication was supported by a 644-patient randomized study. These clinical volumes illustrate increasing demand for biomarker-selected, intravenously delivered and combination-ready therapies.

United States Next-Generation Cancer Therapeutics Market Drivers

Biomarker Expansion and Precision Medicine Accelerate United States Next-Generation Cancer Therapeutics Market Growth

The principal driver is the expanding clinically actionable biomarker universe across lung, breast, prostate and hematologic malignancies. FDA activity increasingly encompasses ROS1, RET, BRCA2, ESR1, HER2 and other molecularly defined populations. In July 2026 alone, approvals included ROS1-positive NSCLC and RET fusion-positive solid tumors, while 2025 approvals covered BRCA2-mutated prostate cancer and ESR1-mutated breast cancer. Trial populations commonly reach hundreds of patients, including 644 patients for TROPION-Breast02 and 732 for TROPION-Breast01, supporting increasingly specialized treatment pathways.

United States Next-Generation Cancer Therapeutics Market Restraints

Manufacturing Complexity and Treatment Toxicity Constrain Advanced Therapy Deployment

Autologous cell therapies require patient-specific collection, manufacturing, conditioning and infusion infrastructure, limiting throughput compared with conventional oral drugs. Lifileucel's study reported a 31.5% response rate, but FDA labeling also highlights severe cytopenia, infection and organ-related risks. Among responders, 56.5%, 47.8% and 43.5% maintained responses without progression or death at 6, 9 and 12 months, respectively, illustrating both meaningful efficacy and the intensive monitoring requirements accompanying advanced cellular treatment.

United States Next-Generation Cancer Therapeutics Market Opportunities

Broader Administration Settings Support United States Next-Generation Cancer Therapeutics Market Demand

Treatment decentralization represents a major opportunity as subcutaneous formulations, oral targeted drugs and streamlined cellular-therapy requirements expand administration flexibility. In June 2025, FDA eliminated REMS requirements for approved BCMA- and CD19-directed autologous CAR-T therapies. By December 2025, subcutaneous amivantamab gained approval across indications of its IV formulation, while July 2026 brought subcutaneous isatuximab approval for multiple-myeloma indications. These changes can broaden delivery beyond highly restrictive treatment workflows while reducing infusion dependence.

Challenges in United States Next-Generation Cancer Therapeutics Market

Clinical Sequencing and Combination Selection Increase Treatment Complexity

The growing number of therapeutic permutations creates sequencing, toxicity and biomarker-selection challenges. Datroway is administered at 6 mg/kg every 21 days, while its pivotal trial randomized 732 patients against four chemotherapy alternatives. FDA data reported stomatitis in 59%, nausea in 56%, fatigue in 44% and alopecia in 38% of treated patients, emphasizing the need to balance efficacy with toxicity as next-generation regimens move into earlier treatment lines.

United States Next-Generation Cancer Therapeutics Market Segmentation

Therapy segmentation shows immunotherapy holding approximately 31.95% of 2026 revenue, ahead of targeted therapy at 30.07%. Cancer-type segmentation is led by lung cancer at approximately 33.61%, followed by breast cancer at 18.56%, with the supplied datasets indicating different totals because they represent independent segmentation views.

By Therapy Type

Immunotherapy is the largest therapy category, increasing from USD 6,693.65 million in 2025 to USD 7,204.38 million in 2026 and USD 12,973.68 million by 2034 at a 7.63% CAGR. Its 2026 contribution is approximately 31.95%.

Targeted therapy is the fastest-growing listed therapy category at 7.99% CAGR, advancing from USD 6,780.93 million in 2026 to USD 12,541.73 million in 2034. Cell therapy follows closely at 7.98%, compared with 7.69% for ADCs and 7.44% for gene therapy.

By Cancer Type

Lung cancer is the largest cancer category at USD 7,567.42 million in 2026 and is forecast to reach USD 13,217.64 million by 2034 at 7.22% CAGR. It represents approximately 33.61% of the supplied 2026 cancer-type total.

Prostate cancer records the highest listed CAGR at 7.93%, compared with 7.89% for colorectal cancer and 7.86% for blood cancers. Prostate therapeutics rise from USD 1,807.24 million in 2026 to USD 3,327.78 million in 2034.

By Modality

The market comprises monotherapy and combination therapy, including immunotherapy plus targeted agents, chemotherapy plus ADCs, and mRNA plus checkpoint inhibitors. Numerical modality-specific revenue and CAGR values were not supplied and are therefore not extrapolated.

Combination strategies are gaining clinical relevance, with FDA approvals in 2026 including pembrolizumab plus enfortumab vedotin and gedatolisib plus fulvestrant, with or without palbociclib. These approvals demonstrate multi-agent treatment expansion without requiring unsupported modality revenue estimates.

By Route of Administration

Administration routes comprise IV, oral, intratumoral/localized and subcutaneous delivery. Datroway uses IV administration at 6 mg/kg every 3 weeks, while 2026 approvals included subcutaneous isatuximab, demonstrating diversification of delivery formats.

Route-specific revenue and CAGR figures were not provided. Consequently, no artificial dominance percentage is assigned to IV, oral, localized or subcutaneous therapies.

By Mechanism of Action

Mechanisms include checkpoint-mediated immune activation, oncogene targeting, DNA-damage-response modulation, tumor-microenvironment modulation and apoptosis induction. FDA's July 2026 ROS1-targeted NSCLC approval and RET fusion-positive solid-tumor approval illustrate continuing expansion of molecularly targeted mechanisms.

Mechanism-specific market values and CAGRs were not included in the supplied dataset. Accordingly, numerical dominance is not inferred beyond the therapy and cancer-type categories supported by mandatory data.

By End-User

Specialized cancer hospitals, academic institutes, ambulatory infusion centers and homecare constitute the principal end-user groups. Advanced cell therapies remain infrastructure-intensive, while oral and subcutaneous products support progressively decentralized treatment pathways.

No end-user revenue or CAGR dataset was supplied. The June 2025 elimination of CAR-T REMS requirements nevertheless indicates a regulatory shift capable of expanding treatment-site flexibility for approved BCMA- and CD19-directed therapies.

United States Next-Generation Cancer Therapeutics Market Counties Outlook

The supplied mandatory dataset provides national U.S. totals rather than county-level revenue. Consequently, county percentages, production values and county CAGRs cannot be calculated without introducing unsupported numerical assumptions. National therapy revenue totals USD 22,550.44 million in 2026 and USD 40,943.14 million in 2034, while the cancer-type dataset totals USD 22,515.91 million and USD 40,386.89 million, respectively.

At the national level, immunotherapy contributes approximately 31.95% and targeted therapy 30.07% of 2026 therapy revenue. Lung cancer contributes approximately 33.61% of the cancer-type dataset, breast cancer 18.56%, colorectal cancer 14.39%, blood cancers 12.43%, prostate cancer 8.03%, brain cancer 6.79%, and pan-tumor therapies 6.19%.

Top players in United States Next-Generation Cancer Therapeutics Market

• Merck & Co., Inc.
• Bristol Myers Squibb
• Johnson & Johnson
• AstraZeneca
• Roche/Genentech
• Novartis
• Pfizer
• Gilead Sciences
• Eli Lilly and Company
• Amgen
• Daiichi Sankyo
• Regeneron Pharmaceuticals
• Sanofi
• Iovance Biotherapeutics
• Legend Biotech

Top Two Companies

• Merck & Co., Inc

 A defensible company-specific percentage share cannot be calculated from the supplied tables because manufacturer-level sales are not provided. Merck maintains broad positioning through checkpoint inhibition and combination regimens. In July 2026, FDA expanded pembrolizumab-based treatment with enfortumab vedotin for muscle-invasive bladder cancer, adding to the company's extensive immuno-oncology footprint. The regimen's movement across neoadjuvant and adjuvant settings illustrates the strategic importance of checkpoint-based combinations.

• AstraZeneca/Daiichi Sankyo

ecosystem Manufacturer-specific percentage share is likewise unavailable from the mandatory dataset. The partnership is strongly positioned in ADCs through deruxtecan-based platforms. Datroway received its initial U.S. approval in January 2025 following a 732-patient trial, and FDA expanded its use to unresectable or metastatic TNBC in May 2026 based on a 644-patient randomized study.

Recent Developments in United States Next-Generation Cancer Therapeutics Market

• 2026:FDA approved zidesamtinib for previously treated ROS1-positive locally advanced or metastatic NSCLC on July 22.
• 2026:FDA approved gedatolisib plus fulvestrant, with or without palbociclib, for selected HR-positive/HER2-negative advanced breast cancer on July 14.
• 2026:FDA approved Datroway for unresectable or metastatic TNBC patients not eligible for PD-1/PD-L1 inhibitor therapy on May 22, supported by a 644-patient study.
• 2025:FDA approved Breyanzi as the first U.S. CAR-T therapy for marginal zone lymphoma after at least 2 prior treatment lines.

Research Methodology

The analysis uses 2025 as the base year, 2026 as the current year and 2026–2034 as the forecast horizon. All market values, segment contributions and CAGRs in the introduction, segmentation and national outlook are derived directly from the mandatory supplied datasets. Percentage contributions were calculated by dividing individual 2026 segment values by their respective supplied totals. External evidence is restricted to contextual validation of regulatory approvals, clinical-trial volumes, administration patterns and technology developments, principally using FDA sources. No unsupported county, modality, route, mechanism, end-user or manufacturer revenue estimates were introduced where numerical source data were unavailable.